LMY-922 Market Summary

Key Factors Driving LMY-922 Growth

1. Potential to target multiple B-cell receptors

LMY-922 is designed to use BAFF as a targeting ligand, potentially engaging BAFF receptors expressed across B-cell populations rather than relying exclusively on a single conventional CAR-T target such as CD19. This strategy may help address disease-associated B cells that persist after existing targeted therapies. If clinical studies demonstrate effective depletion of relevant B-cell populations, the approach could provide a differentiated treatment option for patients with refractory disease. This remains a therapeutic hypothesis to be tested, not a proven clinical advantage.

2. Development opportunity in refractory hematologic malignancies

The company received FDA IND clearance in March 2026 for a Phase I study of LMY-922 in refractory hematologic malignancies. The registered study, NCT07679919, plans to enrol approximately 27 participants and evaluate safety, dose-limiting toxicities, and preliminary antitumour activity. The trial includes conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukaemia, hairy-cell leukaemia, and multiple myeloma. These settings represent potential areas of unmet need, particularly for patients whose disease has relapsed after previous treatments.

3. Potential to address autoimmune diseases

LMY-922 also has a potential development pathway in refractory autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, dermatomyositis, and systemic sclerosis. Luminary received FDA IND clearance in July 2026 for a Phase I autoimmune basket study, NCT07729995, with an estimated enrolment of 94 participants. The study is designed to evaluate safety and dosing, with disease-specific measures used to explore preliminary responses. This broader indication strategy could expand the candidate's commercial potential if clinical benefit is demonstrated across multiple conditions.

4. Allogeneic γδ CAR-T platform and manufacturing potential

Luminary describes its platform as an off-the-shelf approach using healthy-donor cells, with the aim of producing hundreds of doses from one donor and storing cryopreserved products for use when needed. If these manufacturing goals are achieved, the platform could reduce patient-specific production delays and potentially improve treatment accessibility compared with conventional autologous CAR-T therapies. However, these are company-stated platform objectives; LMY-922-specific production costs, manufacturing yields, and commercial scalability have not yet been established publicly.

5. Potential use after failure of existing B-cell-directed therapies

The hematologic malignancy trial is specifically intended to investigate patients whose disease has relapsed or proved refractory, including after previous CD19-targeted treatment. A different targeting strategy could be valuable for patients whose cancers persist despite existing approaches. If LMY-922 demonstrates activity in these difficult-to-treat populations, it may have a differentiated position within the CAR-T landscape. At present, there are no published human efficacy results establishing that it overcomes resistance to CD19-directed therapies.

LMY-922 Recent Developments

In July 2026, Luminary Therapeutics announced that the US Food and Drug Administration had cleared the investigational new drug application for the autoimmune-disease program, enabling clinical development to proceed. The studies are designed to assess safety, tolerability, dose-limiting toxicities, and preliminary therapeutic activity. Potential risks include cytokine release syndrome, neurotoxicity, infections, and excessive depletion of healthy B cells.

“LMY-922 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of LMY-922 for potential indication like Chronic lymphocytic leukaemia, Rheumatoid arthritis, and Systemic lupus erythematosus in the 7MM. A detailed picture of LMY-922’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the LMY-922 for potential indications. The LMY-922 market report provides insights about LMY-922’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current LMY-922 performance, future market assessments inclusive of the LMY-922 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of LMY-922 sales forecasts, along with factors driving its market.

LMY-922 Drug Summary

LMY-922, is an investigational allogeneic, B-cell activating factor (BAFF) ligand-directed chimeric antigen receptor T-cell (CAR-T) therapy developed by Luminary Therapeutics for the treatment of refractory hematological malignancies and autoimmune diseases. The therapy uses donor-derived T cells, including gamma-delta (γδ) T cells, that are genetically engineered through a non-viral transposon system to express a CAR incorporating BAFF ligand. This design enables the engineered cells to recognize and target three members of the BAFF receptor family: BAFF receptor (BAFF-R/BR3), B-cell maturation antigen (BCMA), and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), which are expressed on B-cell populations and plasma cells involved in certain malignancies and autoimmune disorders. By targeting multiple receptors, LMY-922 aims to eliminate disease-driving B cells and antibody-producing plasma cells, potentially overcoming limitations associated with therapies that target a single antigen, such as CD19. Its allogeneic design also offers the potential for standardized, off-the-shelf manufacturing rather than individualized production from each patient. The clinical development program includes a Phase I study (NCT07679919) evaluating LMY-922 in patients with refractory non-Hodgkin lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, and multiple myeloma. A separate Phase I study (NCT07729995) is planned to investigate its potential in refractory autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, dermatomyositis, and systemic sclerosis. The report provides LMY-922’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the LMY-922 Market Report

The report provides insights into:

• A comprehensive product overview including the LMY-922 MoA, description, dosage and administration, research and development activities in potential indication like Chronic lymphocytic leukaemia, Rheumatoid arthritis, and Systemic lupus erythematosus.
• Elaborated details on LMY-922 regulatory milestones and other development activities have been provided in LMY-922 market report.
• The report also highlights LMY-922‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The LMY-922 market report also covers the patents information, generic entry and impact on cost cut.
• The LMY-922 market report contains current and forecasted LMY-922 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The LMY-922 market report also features the SWOT analysis with analyst views for LMY-922 in potential indications.

Methodology

The LMY-922 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LMY-922 Analytical Perspective by DelveInsight

• In-depth LMY-922 Market Assessment

This LMY-922 sales market forecast report provides a detailed market assessment of LMY-922 for potential indication like Chronic lymphocytic leukaemia, Rheumatoid arthritis, and Systemic lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted LMY-922 sales data uptil 2034.

• LMY-922 Clinical Assessment

The LMY-922 market report provides the clinical trials information of LMY-922 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

LMY-922 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

LMY-922 Market Potential & Revenue Forecast

• Projected market size for the LMY-922 and its key indications
• Estimated LMY-922 sales potential (LMY-922 peak sales forecasts)
• LMY-922 Pricing strategies and reimbursement landscape

LMY-922 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• LMY-922 Market positioning compared to existing treatments
• LMY-922 Strengths & weaknesses relative to competitors

LMY-922 Regulatory & Commercial Milestones

• LMY-922 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

LMY-922 Clinical Differentiation

• LMY-922 Efficacy & safety advantages over existing drugs
• LMY-922 Unique selling points

LMY-922 Market Report Highlights

• In the coming years, the LMY-922 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The LMY-922 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LMY-922’s dominance.
• Other emerging products for Chronic lymphocytic leukaemia, Rheumatoid arthritis, and Systemic lupus erythematosus are expected to give tough market competition to LMY-922 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LMY-922 in potential indications.
• Analyse LMY-922 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted LMY-922 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of LMY-922 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of LMY-922? How strong is LMY-922’s clinical and commercial performance?
• What is LMY-922’s clinical trial status in each individual indications such as Chronic lymphocytic leukaemia, Rheumatoid arthritis, and Systemic lupus erythematosus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LMY-922 Manufacturers?
• What are the key designations that have been granted to LMY-922 for potential indications? How are they going to impact LMY-922’s penetration in various geographies?
• What is the current and forecasted LMY-922 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of LMY-922 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to LMY-922 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is LMY-922? What is the duration of therapy and what are the geographical variations in cost per patient?